Merit Medical Systems Inc. filings document operating and financial results, Regulation FD disclosures and material events for a medical-device manufacturer serving interventional, diagnostic and therapeutic markets. Recent Form 8-K reports cover quarterly and annual results, conference-call materials, historical revenue information under the Foundational and Therapeutic product categories, and product-related updates.
The company’s proxy materials describe board composition, governance practices, executive compensation and shareholder voting matters. Other filed event reports address board-leadership changes, completed product-technology acquisitions, capital-structure disclosure categories and clinical or regulatory disclosures tied to Merit’s device portfolio.
Merit Medical Systems reported solid growth for the quarter and first half of 2026. Net sales reached $418.8 million for Q2 and $800.7 million year-to-date, up 9.5% and 8.5% from 2025. Gross profit margin improved to 51.4% in Q2, lifting income from operations to $60.4 million. Net income was $38.8 million for Q2 and $79.8 million for the first six months, with diluted EPS of $0.65 and $1.33, respectively.
Foundational products generated $281.0 million of Q2 revenue and therapeutic products $137.9 million, with strong growth in cardiac therapies and endoscopy platforms. Merit completed the View Point Medical acquisition for $137.3 million net of cash, following earlier Biolife and C2 CryoBalloon deals, and sold the DualCap product line for $28 million, recording a $12.5 million gain. Cash and cash equivalents were $448.7 million, with $736.3 million of convertible notes outstanding and no borrowings under the $700 million revolving credit facility.
Merit Medical Systems, Inc. reported strong second-quarter 2026 results, with net sales of $418.843 million, up 10% year-over-year and 9% on a constant currency basis. Management highlighted 9% organic, constant currency revenue growth excluding a strategic divestiture and 10% growth in U.S. sales. GAAP gross margin improved to 51.4% and non-GAAP gross margin to 55.8%. GAAP net income was $38.8 million ($0.65 per diluted share), while non-GAAP net income was $71.3 million ($1.19 per share), an 18% year-over-year increase.
GAAP operating margin rose to 14.4% and non-GAAP operating margin to 22.6%. For the first six months, free cash flow was $76.6 million. As of June 30, 2026, the company held $448.7 million in cash and cash equivalents, total debt obligations of $747.5 million, and approximately $697 million of available borrowing capacity.
Merit raised its full-year 2026 outlook, now guiding total revenue to $1.631–$1.643 billion (7.6–8.4% growth) and non-GAAP earnings per share to $4.25–$4.35, implying 11–14% growth, compared with prior EPS guidance of $4.01–$4.15. Management continues to target its three-year Continued Growth Initiative financial objectives through 2026.
Merit Medical Systems chief human resources officer Michel J. Voigt reported a Form 4 showing a bona fide charitable gift of 65 shares of common stock on June 15, 2026, with no consideration received. After this gift, he holds 46,062 common shares directly and 2,265 additional shares through a 401(k) plan. He also retains non-qualified stock options covering 11,076 shares at an exercise price of $70.58, 4,046 shares at $65.03, and 2,420 shares at $56.25, vesting in 25% annual installments and expiring between 2028 and 2030. The filing reflects a small charitable disposition rather than a market sale.
MERIT MEDICAL SYSTEMS INC chief legal officer Brian G. Lloyd reported a bona fide charitable gift of 2,000 shares of common stock at a reported price of $0.00 per share. The filing notes that no consideration was received for this transaction.
Following the gift, he directly holds 60,132 common shares and also has indirect ownership of 2,000 shares through a 401(k) plan. In addition, he retains several grants of non-qualified stock options to buy common stock at exercise prices ranging from $37.71 to $70.58, with expiration dates between 2027 and 2030.
MERIT MEDICAL SYSTEMS INC director Thomas J. Gunderson exercised stock options to acquire 21,250 shares of common stock. On May 20, 2026, he exercised two non-qualified stock option grants for 7,500 and 13,750 shares at an exercise price of $52.17 per share, paying the exercise prices in cash. The footnote states that no shares were sold in connection with these option exercises. Following the transactions, he directly owns 60,741 shares of common stock, and the exercised option grants now have zero remaining option shares.
Ward Lynne N. reported acquisition or exercise transactions in this Form 4 filing.
MERIT MEDICAL SYSTEMS INC director Lynne N. Ward received an equity grant. On this Form 4, she was awarded 3,457 shares of Common Stock through restricted stock units at a price of $0.00 per share as a compensation grant, not an open-market trade.
The RSUs were granted under the Merit Medical Systems, Inc. 2026 Equity Incentive Plan and will vest on May 3, 2027, subject to her continued service to the company through that date. After this award, her directly held common stock position reported in the filing is 11,266 shares.
Ward Scott R. reported acquisition or exercise transactions in this Form 4 filing.
Merit Medical Systems director Scott R. Ward received an equity award of 3,457 shares. The Form 4 reports a grant of 3,457 restricted stock units under the company’s 2026 Equity Incentive Plan at no purchase price. These RSUs will vest on May 3, 2027, subject to his continued service with the company through the vesting date. Following this award, his reported direct holdings from this grant total 3,457 shares of common stock-equivalent units, reflecting routine, compensation-related equity rather than an open-market purchase or sale.
MERIT MEDICAL SYSTEMS INC director Thomas J. Gunderson reported an equity award and his current holdings. He received a grant of 3,457 restricted stock units under the Merit Medical Systems, Inc. 2026 Equity Incentive Plan. These RSUs vest on May 3, 2027, subject to his continued service with the company through that date.
Following the award, Gunderson directly holds 39,491 shares of Common Stock. He also holds non-qualified stock options to acquire 7,500 and 13,750 shares of Common Stock at an exercise price of $52.17 per share, expiring on May 31, 2026 and May 24, 2026, respectively.
Evans Stephen C. reported acquisition or exercise transactions in this Form 4 filing.
Merit Medical Systems director Stephen C. Evans received a grant of 3,457 restricted stock units (RSUs). The award was made as common stock on a grant/award basis at no cash cost and increases his directly held common shares to 10,266 after the transaction.
The RSUs were granted under the Merit Medical Systems, Inc. 2026 Equity Incentive Plan and will vest on May 3, 2027, subject to his continued service with the company through that vesting date. This is a routine equity compensation grant rather than an open-market share purchase or sale.
Kaiser Laura S. reported acquisition or exercise transactions in this Form 4 filing.
MERIT MEDICAL SYSTEMS INC director Laura S. Kaiser reported receiving an equity grant rather than making an open-market trade. She was awarded 3,457 shares of common stock in the form of restricted stock units under the company’s 2026 Equity Incentive Plan at no cash cost to her.
The RSUs will vest on May 3, 2027, if she continues to serve the company through that date. After this grant, her reported direct holdings total 13,352 shares of common stock, reflecting a routine compensation-related award rather than a discretionary stock purchase or sale.